• Reported GAAP EPS of $0.16 up 100.00% YoY • Reported revenue of $14.54M up 27.43% YoY • BrainsWay expects full-year 2026 revenue of $66M to $68M, representing 27% to 30% growth, with operating income targeted at 13% to 14% and Adjusted EBITDA of $12M to $14M.
Bullish
BrainsWay achieved strong 27% revenue growth in Q4 and full-year 2025, expanded its Deep TMS system's FDA label for adolescent MDD, and saw remaining performance obligations increase 43%.
Bearish
BrainsWay experienced negative net cash from operating activities in Q4 2025 and flat full-year gross margin, alongside risks related to timely regulatory approvals and financing potential investments.